Wockhardt sees Q2 revenue surge, driven by antibiotic innovation and biosimilar expansion
Wockhardt Limited, a leading pharmaceutical and biotechnology company, released its second-quarter financial results for the fiscal year 2024-25, showing significant growth across several critical areas. ... Read More
Cipla boosts investment in Ethris to advance mRNA therapies in emerging markets
Cipla Limited has announced an additional investment of EUR 3 million in Ethris GmbH, further strengthening its involvement in the mRNA technology sector. This move ... Read More